RxDoctor Payments Data

Kristen Hickok

Family · Palm Springs, CANPI 1497380992

Payments from drug & device makers

$5,708in general payments, 2019–2025

Across 275 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Boston Scientific$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$369
  • Collegium Pharmaceutical, Inc.$268
  • Painteq LLC$197
  • Pfizer$188
  • plus $472 from 12 others

What the payments were for

  • Food & beverage$5,701100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,708 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$87,931
Medicare patients
252
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl36$30,443
OxycontinOxycodone Hcl54$27,960
ZtlidoLidocaine36$23,739
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen666$17,045
MovantikNaloxegol Oxalate42$16,358
Lidocaine124$14,408
UbrelvyUbrogepant11$11,407
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen340$10,221
Diclofenac Sodium206$9,735
Buprenorphine42$8,944
Naloxone Hcl101$6,585
Gabapentin369$5,303
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$5,145
Oxycodone Hcl134$3,985
Pregabalin205$3,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$268$30,44336 claims
Scilex Pharmaceuticals Inc.Ztlido$147$23,73936 claims
AbbVieUbrelvy$2,614$11,40711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →